Phillip Parente

3.9k total citations
82 papers, 1.5k citations indexed

About

Phillip Parente is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Phillip Parente has authored 82 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Oncology, 45 papers in Pulmonary and Respiratory Medicine and 15 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Phillip Parente's work include Prostate Cancer Treatment and Research (34 papers), Radiopharmaceutical Chemistry and Applications (12 papers) and Immunotherapy and Immune Responses (12 papers). Phillip Parente is often cited by papers focused on Prostate Cancer Treatment and Research (34 papers), Radiopharmaceutical Chemistry and Applications (12 papers) and Immunotherapy and Immune Responses (12 papers). Phillip Parente collaborates with scholars based in Australia, United Kingdom and United States. Phillip Parente's co-authors include Ian D. Davis, Jonathan Cebon, Madeleine King, Michael Jefford, Wee Kheng Soo, Pēteris Dārziņš, A. L. Pope, Eugene Maraskovsky, Wendie Hopkins and Nektaria Dimopoulos and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Phillip Parente

81 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Phillip Parente Australia	21	698	438	420	258	178	82	1.5k
Manuel Rodrigues France	20	611 0.9×	185 0.4×	209 0.5×	337 1.3×	56 0.3×	123	1.4k
Daneng Li United States	24	1.8k 2.6×	275 0.6×	690 1.6×	286 1.1×	588 3.3×	136	3.5k
Lindsay M. Kuroki United States	16	368 0.5×	147 0.3×	132 0.3×	358 1.4×	65 0.4×	81	1.3k
Mihaela Cristea United States	25	1.3k 1.8×	283 0.6×	307 0.7×	506 2.0×	39 0.2×	110	2.2k
Nicolò Matteo Luca Battisti United Kingdom	21	922 1.3×	68 0.2×	398 0.9×	109 0.4×	359 2.0×	81	1.6k
Alice Indini Italy	23	999 1.4×	226 0.5×	355 0.8×	371 1.4×	22 0.1×	82	1.7k
Ashley Rosko United States	20	713 1.0×	110 0.3×	81 0.2×	461 1.8×	230 1.3×	122	1.4k
Yanin Chávarri-Guerra Mexico	19	672 1.0×	58 0.1×	194 0.5×	160 0.6×	99 0.6×	81	1.3k
Sheetal Kircher United States	22	972 1.4×	166 0.4×	210 0.5×	137 0.5×	27 0.2×	108	1.8k
Deniz Can Güven Türkiye	20	851 1.2×	138 0.3×	440 1.0×	265 1.0×	25 0.1×	164	1.6k

Countries citing papers authored by Phillip Parente

Since Specialization

Citations

This map shows the geographic impact of Phillip Parente's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Phillip Parente with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Phillip Parente more than expected).

Fields of papers citing papers by Phillip Parente

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Phillip Parente. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Phillip Parente. The network helps show where Phillip Parente may publish in the future.

Co-authorship network of co-authors of Phillip Parente

This figure shows the co-authorship network connecting the top 25 collaborators of Phillip Parente. A scholar is included among the top collaborators of Phillip Parente based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Phillip Parente. Phillip Parente is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Williams, Colin C., Wei Hong, A. Antón, et al.. (2025). Treatment patterns and outcomes for younger patients with metastatic castration-resistant prostate cancer (mCRPC); An Australian prospective registry study. Clinical Genitourinary Cancer. 23(3). 102345–102345. 1 indexed citations

Dennett, Amy M, Katherine E. Harding, Casey L. Peiris, et al.. (2025). Feasibility of increasing physical activity levels of hospitalized cancer survivors using goal setting and feedback (CanFit): a randomized controlled trial. Physiotherapy. 128. 101776–101776.

Antón, A., Natalie WH Tan, Phillip Parente, et al.. (2024). Impact of Comorbidities and Drug Interactions in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Androgen Receptor Pathway Inhibitors. JCO Oncology Practice. 20(9). 1231–1242. 1 indexed citations

Antón, A., Shirley Wong, Andrew Weickhardt, et al.. (2021). Real-world incidence of symptomatic skeletal events and bone-modifying agent use in castration-resistant prostate cancer – an Australian multi-centre observational study. European Journal of Cancer. 157. 485–492. 8 indexed citations

Fettke, Heidi, Edmond M. Kwan, Patricia Bukczynska, et al.. (2020). Prognostic Impact of Total Plasma Cell-free DNA Concentration in Androgen Receptor Pathway Inhibitor–treated Metastatic Castration-resistant Prostate Cancer. European Urology Focus. 7(6). 1287–1291. 13 indexed citations

Jensen, Allan, Jeremy Shapiro, Andrew Weickhardt, et al.. (2020). 226P Use of PSMA PET in metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. 31. S1329–S1330. 1 indexed citations

Davies, Heather, Craig Underhill, Robert Blum, et al.. (2020). Victorian Lung Cancer Service Redesign Project: impacts of a quality improvement collaborative on timeliness and management in lung cancer. Internal Medicine Journal. 51(12). 2061–2068. 5 indexed citations

Shapiro, Jeremy, Andrew Weickhardt, Lavinia Spain, et al.. (2020). 225P Prostate cancer treatments and outcomes in the elderly: A retrospective analysis of an Australian real-world cohort. Annals of Oncology. 31. S1329–S1329. 1 indexed citations

Kwan, Edmond M., Heidi Fettke, Maria Docanto, et al.. (2019). Prognostic Utility of a Whole-blood Androgen Receptor-based Gene Signature in Metastatic Castration-resistant Prostate Cancer. European Urology Focus. 7(1). 63–70. 11 indexed citations

10.

Fettke, Heidi, Edmond M. Kwan, Andrew Mant, et al.. (2018). Plasma Cell-Free DNA (cfDNA) Concentration and Outcomes in Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Patients Treated with Androgen Receptor Signalling Inhibitors (ARSIs). Asia-Pacific Journal of Clinical Oncology. 14. 29–29. 1 indexed citations

11.

Lee, Dae Ho, Hiroshi Isobe, Hubert Wirtz, et al.. (2018). Health care resource use among patients with advanced non-small cell lung cancer: the PIvOTAL retrospective observational study. BMC Health Services Research. 18(1). 147–147. 21 indexed citations

12.

Pezaro, Carmel, et al.. (2017). Comparison of first-line treatment options for metastatic castrate resistant prostate cancer: A retrospective cohort study. Annals of Oncology. 28. x77–x78. 1 indexed citations

13.

Bergin, Alice R.T., Elizabeth Hovey, Andrew R. Lloyd, et al.. (2017). Docetaxel-related fatigue in men with metastatic prostate cancer: a descriptive analysis. Supportive Care in Cancer. 25(9). 2871–2879. 9 indexed citations

14.

Bono, Johann S. de, Lajos Géczi, Daniel Ford, et al.. (2016). PROSELICA: Health-related quality of life (HRQL) and post-hoc analyses for the phase 3 study assessing cabazitaxel 20 (C20) vs 25 (C25) mg/m2 post-docetaxel (D) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. 27. vi245–vi245. 2 indexed citations

15.

Wong, Hui‐Li, Sheau Wen Lok, Shirley Wong, Phillip Parente, & Mark Rosenthal. (2015). Docetaxel in very elderly men with metastatic castration-resistant prostate cancer. Prostate International. 3(2). 42–46. 14 indexed citations

16.

Klein, Oliver, Ian D. Davis, Grant A. McArthur, et al.. (2015). Low-dose cyclophosphamide enhances antigen-specific CD4+ T cell responses to NY-ESO-1/ISCOMATRIX™ vaccine in patients with advanced melanoma. Cancer Immunology Immunotherapy. 64(4). 507–518. 32 indexed citations

17.

Goldstein, David, Melanie L. Bell, Phyllis Butow, et al.. (2014). Immigrants' perceptions of the quality of their cancer care: an Australian comparative study, identifying potentially modifiable factors. Annals of Oncology. 25(8). 1643–1649. 36 indexed citations

18.

Hovey, Elizabeth, Paul de Souza, Gavin Marx, et al.. (2013). Phase III, randomized, double-blind, placebo-controlled study of modafinil for fatigue in patients treated with docetaxel-based chemotherapy. Supportive Care in Cancer. 22(5). 1233–1242. 27 indexed citations

19.

Parente, Phillip, Francis Parnis, & Howard Gurney. (2012). Emerging and second line therapies for the management of metastatic castration‐resistant prostate cancer: The Australian perspective. Asia-Pacific Journal of Clinical Oncology. 8(1). 31–42. 5 indexed citations

20.

Davis, Ian D., Qiyuan Chen, Phillip Parente, et al.. (2006). Blood Dendritic Cells Generated With Flt3 Ligand and CD40 Ligand Prime CD8+ T Cells Efficiently in Cancer Patients. Journal of Immunotherapy. 29(5). 499–511. 57 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact